Vertex Pharmaceuticals Incorporated (VRTX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 392.81 |
| Open | 392.81 |
| Bid | 402.16 x 100 |
| Ask | 402.77 x 200 |
| Day's range | 392.47 - 406.90 |
| 52-week range | 320.01 - 448.40 |
| Volume | |
| Avg. volume | 1,116,068 |
| Market cap | 103.937B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 28.97 |
| EPS (TTM) | 13.88 |
| Earnings date | 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 465.42 |
ZacksWill Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksVertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
ZacksVertex (VRTX) to Report Q1 Earnings: What's in the Cards?
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
© 2024 Yahoo. All rights reserved.